Back to search
Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis trials you may qualify forThe main objective of this study is to explore the efficacy of avacopan in participants affected by AAV.
This is a phase 1 study designed to evaluate the safety, pharmacokinetics (PK), and anti-B-cell activity of FT819 following treatment with or without auxiliary…
The purpose of this study is to determine the 72-hour pharmacokinetics of emulsified avacopan at a dose of 30 mg twice daily given to up to 6 patients with acti…
The primary objective of this study is to evaluate the long-term safety of avacopan in participants with antineutrophil cytoplasmic antibody (ANCA)-associated v…
The primary aim is to study the efficacy of treatment with BDB-001 Injection to induce remission in patients with active anti-neutrophil cytoplasmic antibody (A…
The main purpose of study is to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of benralizumab.
The purpose of the study is to determine wether a rituximab-based treatment compared to standard therapy (glucocorticoid alone) in patients with microscopic pol…
The purpose of this study is to evaluate the efficacy and safety of obinutuzumab for the treatment of proteinase 3 Anti-Neutrophil Cytoplasmic Antibody (ANCA)-A…
The purpose of this study is to find out whether hydroxychloroquine, in addition to background treatments, reduces disease activity in patients with Anti-Neutro…